Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

Cited In for PubMed (Select 15232326)

1.

Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.

Østergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ; STOP-PD Study Group.

J Affect Disord. 2014 May;160:68-73. doi: 10.1016/j.jad.2013.12.020. Epub 2014 Jan 2.

2.

A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Deligiannidis KM, Rothschild AJ, Barton BA, Kroll-Desrosiers AR, Meyers BS, Flint AJ, Whyte EM, Mulsant BH; STOP-PD Study Group.

J Clin Psychiatry. 2013 Oct;74(10):1003-9. doi: 10.4088/JCP.13m08400.

3.

Measuring psychotic depression.

Østergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ; STOP-PD Study Group.

Acta Psychiatr Scand. 2014 Mar;129(3):211-20. doi: 10.1111/acps.12165. Epub 2013 Jun 25.

4.

The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS.

J Clin Psychopharmacol. 2013 Jun;33(3):391-7. doi: 10.1097/JCP.0b013e31828bf059.

5.

Challenges in the treatment of major depressive disorder with psychotic features.

Rothschild AJ.

Schizophr Bull. 2013 Jul;39(4):787-96. doi: 10.1093/schbul/sbt046. Epub 2013 Apr 18. Review.

6.

Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.

Weissman J, Flint A, Meyers B, Ghosh S, Mulsant B, Rothschild A, Whyte E; STOP-PD Study Group.

Psychiatry Res. 2012 May 30;197(3):221-6. Epub 2012 Mar 31.

7.

Combined venlafaxine and olanzapine prescription in women with psychotic major depression: a case series.

Ghio L, Natta W, Rossi P, Peruzzo L, Zanelli E, Gotelli S, Gabrielli F.

Case Rep Med. 2011;2011:856903. doi: 10.1155/2011/856903. Epub 2011 Apr 4.

8.

Pharmacotherapy for late-life depression.

Alexopoulos GS.

J Clin Psychiatry. 2011 Jan;72(1):e04. doi: 10.4088/JCP.7085tx2cj.

9.

Does comorbid posttraumatic stress disorder affect the severity and course of psychotic major depressive disorder?

Gaudiano BA, Zimmerman M.

J Clin Psychiatry. 2010 Apr;71(4):442-50. doi: 10.4088/JCP.08m04794gre. Epub 2009 Dec 15.

10.

A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M; STOP-PD Group.

Arch Gen Psychiatry. 2009 Aug;66(8):838-47. doi: 10.1001/archgenpsychiatry.2009.79. Erratum in: Arch Gen Psychiatry. 2011 Jun;68(6):626.

11.

Marked effect of milnacipran combined with olanzapine for a delusional depressive patient.

Sugawara Y, Higuchi H, Yoshida K, Shimizu T.

Neuropsychiatr Dis Treat. 2005 Dec;1(4):373-4.

12.

Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.

Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds C 3rd.

Am J Geriatr Psychiatry. 2008 Jan;16(1):21-30. Epub 2007 Oct 10.

13.

Current issues in the classification of psychotic major depression.

Keller J, Schatzberg AF, Maj M.

Schizophr Bull. 2007 Jul;33(4):877-85. Epub 2007 Jun 4. Review.

14.

Augmentation of olanzapine in treatment-resistant schizophrenia.

Zink M.

J Psychiatry Neurosci. 2005 Nov;30(6):409-15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk